Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096458 · ClinicalTrials.gov registry record · Phase 1
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
A Phase 1 study of Gastroesophageal Reflux Disease and Heartburn, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02096458: Completed Phase 1 study of Gastroesophageal Reflux Disease and Heartburn, sponsored by Takeda.
NCT02096458 is a Phase 1 study of Gastroesophageal Reflux Disease and Heartburn that has completed, run by Takeda. The registered enrollment target is 8 participants, below the 356-participant average among 25 other Gastroesophageal Reflux Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096458, a Phase 1 study of Gastroesophageal Reflux Disease and Heartburn, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
Primary Outcome
The disintegration time is the total time from when the participant places the tablet on their tongue until the time at which the participant would normally swallow the remaining materials from the disintegrated tablet. The average disintegration time will be calculated for each participant based on 3 separate tests.
Conditions Studied
Interventions
- DRUG Dexlansoprazole
Study Locations (1)
Massachusetts
- - Woburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
What the finished NCT02096458 record still lists
NCT02096458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 356-participant average among 25 other Gastroesophageal Reflux Disease trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 1 intervention - of which Dexlansoprazole is the first listed.
NCT02096458 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02096458 about?
NCT02096458 is a clinical study titled "Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets". The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
What is the current status of trial NCT02096458?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-02. Estimated completion is 2014-02.
What conditions does trial NCT02096458 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux Disease, Heartburn, Erosive Esophagitis.
What interventions are being tested in trial NCT02096458?
The interventions under investigation include: Dexlansoprazole (DRUG).
Who is sponsoring clinical trial NCT02096458?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02096458 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02096458's enrollment target sits among peer trials
8 26th of 25 the lowest of 25 other Gastroesophageal Reflux Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GCC Agonist Signal in the Small Intestine
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
COMPLETED · Phase 1
-
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
COMPLETED · Phase 1
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia